The dataset's assignee ranking covers 14 companies, and it is led by a single filer with 14 of the 39 records in scope. The top 5 assignees combined account for 84.6% of all records, so ownership is heavily concentrated rather than spread evenly. Beyond the top 10, which together hold 97.4% of records, filers typically appear only once, forming a long tail of single-patent entrants rather than active programmes.

Filing peaked at 17 records in 2019 and had fallen to 5 by the 2022 midpoint, with no rebound visible through the most recent full years in the dataset. That said, publication typically lags filing by around 18 months, so the last one to two years in any trend chart will understate real activity rather than reflect a genuine drop. Treat the apparent decline as a signal to watch, not a confirmed end to R&D investment.

Separation processes (IPC class B01D) appear in 94.9% of the 39 records in scope, and bioreactor and enzyme apparatus (C12M) appear in 76.9%, making these the two anchor classes for the field. Roughly half of records also touch B01J (chemical and physical processes) or C07K (peptides and proteins), reflecting overlap with catalytic media and protein-specific process claims. Because a single record can carry several IPC classes, these shares add up to more than 100% and should not be read as mutually exclusive categories.

The thinner IPC branches in this dataset are A61M (devices for body fluids) and C12P (fermentation and enzymatic synthesis), each covering only 12.8% of the 39 records, alongside B32B (layered products) and G01F (flow and volume measuring) at 20.5% each. These lower shares suggest less claim density around single-use body-fluid-contact formats, fermentation-integrated clarification steps, and in-line flow or turbidity sensing tied to filter media. A first claim combining one of these thinner branches with the dominant B01D separation methods is more likely to find open space than a claim in the core filtration method itself.

US20220081666A1, filed by Ichnos Sciences and published 2022-03-17, discloses methods of cell culture clarification used in manufacturing biopharmaceutical molecules such as antibodies. Its abstract frames the invention specifically around clarification methods within the biopharmaceutical manufacturing process, rather than filter media or hardware design generically. Anyone developing a clarification method for antibody or similar biologic manufacturing should review its claims directly, since method-level filings in this exact use case are one of the more concentrated areas identified in this dataset.